More recently, the Il‐1β inhibitor canakinumab, which also inhibits IL‐6, was trialled in patients with CKD and showed no effect on renal function in terms of serial eGFR, creatinine and urinary albumin‐creatinine ratio.8 Here, IL6 is linked to chronic kidney disease.